Patients' preferences in treatment for neovascular age-related macular degeneration in clinical routine

British Journal of Ophthalmology

Volumn 96, Issue 7, 2012, Pages 997-1002

  Finger, Robert ^a,b   Hoffmann, Andrea E ^c   Fenwick, Eva K ^a   Wolf, Armin ^c   Kampik, Anselm ^c   Kernt, Marcus ^c   Neubauer, Aljoscha S ^c   Hirneiss, Christoph ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESEARCH; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT PARTICIPATION; PATIENT PREFERENCE; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; TREATMENT PLANNING; VISUAL ACUITY; VISUAL ANALOG SCALE;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HEALTH STATUS INDICATORS; HUMANS; INTRAVITREAL INJECTIONS; LANGUAGE; MALE; PATIENT PREFERENCE; PATIENT SATISFACTION; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84862891789     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2011-301201     Document Type: Article

References (14)

1. Chang TS, Bressler NM, Fine JT, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 2007;125:1460-9. (Pubitemid 350106676)
2. Bressler NM, Chang TS, Suner IJ, et al. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010;117:747-56.e4.
3. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd edn. Oxford: Oxford University Press, 2005.
4. Hirneiss C, Rombold F, Kampik A, et al. Visual quality of life after vitreoretinal surgery for epiretinal membranes. Ophthalmologe 2006;103:109-13.
5. Mitchell P, Annemans L, White R, et al. Cost effectiveness of treatments for wet age-related macular degeneration. Pharmacoeconomics 2011;29:107-31.
6. Hirneiss C, Neubauer AS, Gass CA, et al. Visual quality of life after macular hole surgery: outcome and predictive factors. Br J Ophthalmol 2007;91:481-4. (Pubitemid 46623681)
7. Finger RP, Fenwick E, Marella M, et al. The impact of vision impairment on vision-specific quality of life in Germany. Invest Ophthalmol Vis Sci 2011;52:3613-19.
8. Hirneiss C, Rombold F, Kampik A, et al. Visual quality of life after vitreoretinal surgery for epiretinal membranes. Ophthalmologe 2006;103:109-13.
9. Lee BS, Kymes SM, Nease RF Jr, et al. The impact of anchor point on utilities for 5 common ophthalmic diseases. Ophthalmology 2008;115:898-903.e4.
10. Anon. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
11. Marella M, Pesudovs K, Keeffe JE, et al. The psychometric validity of the NEI VFQ-25 for use in a low-vision population. Invest Ophthalmol Vis Sci 2010;51:2878-84.
12. Katz JN, Phillips CB, Fossel AH, et al. Stability and responsiveness of utility measures. Med Care 1994;32:183-8.
13. Bansback N, Czoski-Murray C, Carlton J, et al. Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity. Qual Life Res 2007;16:533-43. (Pubitemid 46363686)
14. Submacular Surgery Trials Research Group. Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ) SST Report Number 19. Ophthalmic Epidemiol 2007;14:205-15.